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ABSTRACT  
Introduction Loss of the cystic fibrosis transmembrane conductance regulator (CFTR) in cystic 
fibrosis (CF) leads to hyperabsorption of sodium and fluid from the airway due to upregulation 
of the epithelial sodium channel (ENaC). Thickened mucus and depleted airway surface liquid 
(ASL) then lead to impaired mucociliary clearance. ENaC regulation is thus a promising target 
for CF therapy. Our aim was to develop siRNA nanocomplexes that mediate effective silencing 
of airway epithelial ENaC in vitro and in vivo with functional correction of epithelial ion and 
fluid transport. 
Methods We investigated translocation of nanocomplexes through mucus and their transfection 
efficiency in primary CF epithelial cells grown at air-liquid interface (ALI). SiRNA-mediated 
silencing was examined by quantitative RT-PCR and Western analysis of ENaC. Transepithelial 
potential (Vt), short circuit current (Isc), ASL depth and ciliary beat frequency (CBF) were 
measured for functional analysis. Inflammation was analysed by histological analysis of normal 
mouse lung tissue sections.  
Results Nanocomplexes translocated more rapidly than siRNA alone through mucus. 
Transfections of primary CF epithelial cells with nanocomplexes targeting αENaC siRNA, 
reduced αENaC and βENaC mRNA by 30%. Transfections reduced Vt, the amiloride-sensitive 
Isc, and mucus protein concentration, while increasing ASL depth and CBF to normal levels. A 
single dose of siRNA in mouse lung silenced ENaC by approximately 30%, which persisted for 
at least 7 days. Three doses of siRNA increased silencing to approximately 50%.  
Conclusion Nanoparticle mediated-delivery of ENaC siRNA to ALI cultures corrected aspects 
of the mucociliary defect in human CF cells and offers effective delivery and silencing in vivo. 
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What is the key question? 
Can silencing of the airway epithelial sodium channel (ENaC) activity correct the mucociliary 
defects associated with the CF epithelium? 
 
 What is the bottom line? 
SiRNA-mediated silencing of ENaC in vitro in pseudostratified, ciliated, air-liquid interface 
(ALI) models of the human airway was shown to correct the electrical and mucociliary defects 
associated with the CF epithelium and, in addition, we demonstrated efficiency of delivery in 
vivo to murine lung and accumulation of the level of silencing by repeated delivery along with 
safety by analysis of inflammation. 
Why read on? 
We have described a siRNA nanoparticle formulation that penetrates mucus to transfect CF 
epithelial cells at ALI and following repeated transfection both at ALI and in vivo demonstrated 
cumulative ENaC silencing to achieve the desired functional effect, providing evidence to 
support its further development as a novel therapeutic approach.  
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INTRODUCTION 
Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance 
regulator gene (CFTR) which encodes a cyclic AMP-activated channel for chloride and other 
anions. 
1-2
 Mutations in CFTR also result in upregulation of the epithelial sodium channel, 
ENaC, leading to imbalanced water and ion movement across the airway epithelium. 
3-4
 This 
results in depletion of the airway surface liquid (ASL) and thickened mucus with progressive 
loss of pulmonary function. 
3-4
 Therefore, ENaC is a promising therapeutic target for CF with the 
potential to restore lung fluid homeostasis and thus improve mucociliary clearance. ENaC is 
comprised of α, β and γ subunits. The pore forming αENaC subunit is required for full channel 
function. The β and γ subunits are regulators of ENaC activity 
5-6
 and residual ENaC activity can 
be measured in their absence. 
5, 7
  The other ENaC subunit, δ, is only expressed at low levels in 
the lung of humans and not at all in rodents. 
8
 
Small molecule ENaC inhibitors such as amiloride 
9
 and benzamil 
10
 reduce sodium 
uptake but their effects are short-lived because of drug absorption. 
11
 Silencing of ENaC 
expression, by short interfering RNA (siRNA)-mediated RNA interference (RNAi), offers a 
more promising therapeutic route. 
12-14
 Potential advantages of nanoparticle-mediated siRNA 
therapy include its potency, specificity, duration, 
15
 and restriction to the airways to prevent 
nephrotoxicity. Transfection of the CF airway epithelium requires protection of siRNA from 
nucleases, penetration of the mucus and periciliary liquid layer (PCL) and targeted uptake by the 
epithelial cells 
16
 with purpose-designed, nanoparticles. Previous attempts to develop ENaC 
siRNA therapies 
17-18
 were limited by lack of nanoparticles capable to effectively deliver siRNA 
to the airway epithelium.  
Receptor-targeted nanocomplexes (RTNs) comprise multi-functional mixtures of cationic 
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liposomes (L) and cationic targeting peptides (P) which self-assemble, electrostatically on 
mixing with siRNA (R). 
19-24
 Peptide E packages nucleic acids through a cationic, oligolysine 
domain and mediates epithelial receptor targeting through a seven amino acid motif, SERSMNF, 
derived by biopanning of a phage peptide library. 
25
 The targeting peptide displays close 
similarity to receptor binding proteins of two intracellular pathogens, rhinovirus and Listeria 
monocytogenes. 
26
 Rhinoviruses bind intercellular adhesion molecule-1 (ICAM-1), that is 
present in the airway epithelium, and upregulated in the inflamed CF epithelium. 
27-28
 Following 
receptor-mediated endocytosis the liposome component destabilises the endosomal bilayer 
allowing nucleic acid release to the cytoplasm before endosomal degradation occurs. 
29
 This 
peptide has been used previously for targeted transfection with plasmid DNA, 
25
 minicircle DNA 
30
 and siRNA 
31
 of bronchial epithelial cells in vitro and in vivo. 
 In this study, we have investigated the effects of RTN-mediated delivery of αENaC 
siRNA on pseudostratified, ciliated, air-liquid interface (ALI) models of the human CF airway, 
particularly the correction of the electrical and mucociliary defects associated with the CF 
epithelium. Finally, we have investigated the translational potential of this therapy by delivery of 
murine αENaC siRNA to the lungs of normal mice to assess in vivo transfection efficacy in a 
surrogate model of the human lung, including efficacy of repeated delivery as well as safety by 
analysis of inflammation. 
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MATERIALS AND METHODS 
Full details are available in the online supplementary material. 
 
Statistics 
Data are expressed as the mean ± standard error of the mean (SEM) and analysed using a two-
tailed, unpaired Student’s t-test or one-way analysis of variance (ANOVA) and Bonferroni’s post 
hoc analysis where applicable. We also report other data as median and interquartile range (IQR) 
and these have been analysed using a Mann-Whitney U non-parametric test. 
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RESULTS 
Assessment of nanocomplex translocation through mucus 
Nanocomplexes containing Cy3-labelled siRNA were added to the surface of the mucus, then the 
cumulative concentration of fluorophores diffusing through the mucus into the lower collection 
chamber over 60 minutes was measured and compared to siRNA alone and fluorescent cationic, 
polystyrene nanoparticles. The concentration of RTNs penetrating through the CF human airway 
mucus barrier at 1 h (figure 1C and Table S1) (441.1 ± 52.7 ng/cm
2
) was 46% 
 
of that collected 
from the normal  human airway mucus barrier at 1 h (961.5 ± 44.8  ng/cm
2
; figure 1B) and this 
was similar for siRNA alone at 43% (390.1 ± 15.8 ng/cm
2
 through CF human airway mucus and 
917.3 ± 60.1  ng/cm
2
 through normal human airway mucus). RTN and siRNA penetration 
through normal mucus were similar at 1 h (figure 1B) (p>0.05, n=6), whereas in porcine gastric 
mucus the RTNs penetrated more rapidly than siRNA (figure 1A) (1046.1 ± 47.6 ng/cm
2 
and
 
472.0 ± 8.8 ng/cm
2
 for RTNs and siRNA alone, respectively; p<0.01, n=6). The rate of 
penetration of pig gastric mucus by cationic polystyrene (PS) nanoparticles (55.0 ± 2.1 nm and 
+23.1 ± 1.1 mV) was not significantly different to siRNA alone (figure 1A; 782.7 ± 123.0 
ng/cm
2 
and
 
472.0 ± 8.8 ng/cm
2
 for PS nanoparticles and siRNA alone, respectively at 1 h) but in 
CF mucus, PS nanoparticles were significantly slower than RTNs or siRNA (figure 1C; 100.0 ± 
57.6 ng/cm
2
 for PS nanoparticles at 1 h compared to the concentrations displayed above which 
were ~4-fold more for both RTNs and siRNA alone; p<0.05, n=6).  
Diffusion coefficients in the three types of mucus (Dm) and water (Dw) were calculated as 
described in the Methods section. Dm/Dw is the relative restriction of diffusion in mucus 
compared to water (Table 1). The diffusion of RTNs was 14-fold higher than that of siRNA 
alone in CF mucus (27-fold impedance for RTNs compared to 376-fold impedance for siRNA 
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alone) despite the nanoparticles being significantly larger (91.9 ± 0.5 nm) and more cationic 
(+35.1 ± 0.6 mV) than molecular siRNA which is approximately 7.5 nm. 
32
 RTNs penetrated 
normal human mucus and pig gastric mucus 8.2 and 12.3-fold faster, respectively, than siRNA 
alone (Table 1).  
 
In vitro siRNA silencing of ENaC in epithelial cells 
Peptide-targeted cationic nanocomplexes were then used to transfect 16HBE14o- epithelial cells 
with siRNA targeting αENaC. Western blot analysis of αENaC protein showed that transfection 
of 16HBE14o- cells with RTNs at 75 nM siRNA led to a decrease in the abundance of both the 
90 kDa and the 65 kDa αENaC protein bands by 41% and 48%, respectively compared to those 
transfected with control siRNA (figures S1A, B). 
 Expression of αENaC in BMI-1 transduced CF bronchial epithelial cells 
33
 (CFBE)  
attained maximal levels after 2-5 days in ALI cultures (figure 2A) and so, ALI culture 
transfections in ongoing experiments were performed after at least 5 days ALI culture. 
Transfections of CFBE monolayers with 100 nM αENaC siRNA, reduced αENaC mRNA by 
30% (n=3) compared to control siRNA-treated cultures (figure 2B). After three sequential 
transfections, performed at 48 h intervals, the level of silencing was improved  to 54% (n=3; 
figure 2B). Silencing of αENaC also resulted in a 51% silencing of βENaC (n=3; Table S2) but 
not the γ subunit (figure 2C). The α subunit in CFBE cells was 74.9 and 19.7-fold overexpressed 
relative to the γ and β subunits, respectively (figure S2, n=3). 
 
Functional effects of ENaC silencing 
We next investigated the effects of αENaC silencing on amiloride-sensitive ENaC-mediated 
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 10
short circuit current (Isc) in CFBE cells cultured at ALI two days after transfection (Figure 3A). 
The amiloride-sensitive Isc was reduced in cells treated with αENaC siRNA (median: 6.4 
µA/cm
2
; IQR: 5.4-9.8 µA/cm
2
; n=6) compared to control siRNA (median: 11.5 µA/cm
2
; IQR: 
10.1-14.1 µA/cm
2
; p<0.05, n=8) or untreated cells (median: 14.3 µA/cm
2
; IQR: 13.2-17.9 
µA/cm
2
; p<0.01, n=5) (figures 3B and 3C; Table S3). As expected, CFBE cells showed a very 
limited response to forskolin (a cAMP agonist) or GlyH-101 (a CFTR inhibitor) under any of the 
conditions examined (figure 3B) as opposed to NHBE cells (figure S3). Transepithelial electrical 
resistance (Rt) was not perturbed by the transfection procedure (figure S4), with ENaC-silenced 
cells having a median of 693.5 (IQR: 565.7-805.8) Ω cm
2
 (n=7) compared to 783.2 (IQR: 711.1-
953.2) Ω cm
2 
and 676.7 (IQR: 653.1-744.2) Ω cm
2 
for control siRNA (n=7) and untreated cells 
(n=3), respectively (Table S3).  
We then performed three sequential siRNA transfections of CFBE cells at 48 h intervals 
and determined physiological responses to ENaC silencing. Mucus was not removed during this 
period (unwashed cells). Samples treated with αENaC siRNA had lower negative transepithelial 
potentials (Vt) (median: -7.2 mV; IQR: -5.7 to -12.2 mV), than those transfected with control 
siRNA (median: -16.0 mV; IQR: -14.8 to -19.0 mV) (figure 3D; n=5) as measured by Scanning 
Ion Conductance Microscopy (SICM).  The median Vt value for the VX-770 and VX-809-treated 
CF cells was -6.8 mV (IQR: -6.7 to -12.7 mV) while for untreated, non-CF cells it was -7.7 mV 
(IQR: -6.3 to -11.6 mV; Table S4). 
The ASL depth in CFBE ALI cultures was increased by ~1.5-fold (median: 12.1 µm ; 
IQR: 10.7-14.9 µm) after silencing of αENaC compared to control siRNA-treated (median: 7.9 
µm; IQR: 6.4-9.8 µm) and untreated cells (median: 8.2 µm; IQR: 5.8-11.1 µm) (p<0.001, n=4) 
(figures 4A and 4B; Table S4). The ciliary beat frequency (CBF) of unwashed CFBE cells 
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increased to 14.5 ± 0.5 Hz from 9.6 ± 0.7 Hz in untreated CFBE cultures following sequential 
treatment with αENaC siRNA (p<0.001, n=10), compared to 11.9 ± 1.0 Hz in control siRNA-
treated cells (p<0.05, n=10) (figure 4C). The CBF of VX-770 and VX-809-treated cells was also 
increased to 12.8 ± 0.5 Hz and (p<0.05, n=10; Table S4).  
Cells treated with αENaC siRNA displayed reduced net fluid absorption rates from the 
apical side of the epithelium with a median value of 0.9 µl/cm
2
/h (IQR: 0.6-1.3 µl/cm
2
/h) which 
was lower than that of both control siRNA-treated cells (median: 1.6; IQR: 1.3-1.9 µl/cm
2
/h; 
p<0.05, n=4) and untreated cells at 1.5 µl/cm
2
/h (IQR: 1.1-1.9 µl/cm
2
/h; figure 4D; Table S4). 
Finally, we measured the total protein concentration in mucus collected from each well of the 
sequentially-transfected CF monolayers. The apical surface of each well was washed with PBS 2 
days after the first (figure 5A) and second transfections (figure 5B) and 7 days after the third 
(figure 5C) transfection. In all cases, the protein concentration in mucus from the αENaC-
silenced cells (n=6) was significantly lower than that from the control siRNA-treated cells (n=6), 
VX-770 and VX-809-treated cells (n=4) or untreated cells (n=3) and this effect lasted for at least 
7 days post-transfection. At the end of the experiment, at 8 days post-transfection with αENaC 
siRNA (n=6), αENaC expression was still 27% lower than control siRNA-treated cells (p<0.05; 
figure 5D).  
 
In vivo lung delivery  
We then investigated delivery of siRNA into the lungs of normal mice to assess the translational 
potential of αENaC siRNA delivery. The biodistribution analysis of nanocomplexes containing 
Dy677-labelled siRNA 24 h after oropharyngeal instillation showed very high retention of 
siRNA in lungs (figure 6A) with low-level fluorescence in intestines (figure S5, p<0.05, n=3) 
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which probably reflects incidental swallowing during administration. There was no fluorescence 
in heart, liver, kidneys and spleen suggesting no detectable transfer of the siRNA from the lung 
to the circulation (figure 6A). Transfecting mice by oropharyngeal instillation with αENaC 
siRNA (n=7) or control siRNA (n=7), silenced αENaC by 30% at the mRNA level compared to 
control siRNA (p<0.01) (figure 6B). Silencing of αENaC 1 week after transfection remained at 
23% compared to control siRNA (figure 6C; n=4 for untreated, n=6 for control siRNA and n=7 
for αENaC siRNA-treated mice) and was not significantly different from silencing at 48 h. 
Repeated transfections with αENaC siRNA (n=8) demonstrated cumulative silencing, increasing 
to 58% reduction compared to control siRNA at 72 h after the third instillation of αENaC siRNA 
(figure 6D; Table S5).  
The RTN siRNA formulations were well tolerated by the mice for single or triple dosing 
(figures S6A, B). H&E staining of lung sections (n=3) showed that treatment with RTNs 
containing ENaC siRNA induced sporadic mild peribronchial cell infiltrates, the size and 
severity of which was unaffected by the number of instillations (figure 7A-B). Control siRNA 
induced a similar inflammatory response although the foci were generally smaller and less 
frequent than with ENaC siRNA (figure 7C). 
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DISCUSSION 
The lack of functional CFTR and hyperactivity of ENaC in the airways of CF patients leads to 
disrupted ion and fluid homeostasis. 
3
 Modulators of CFTR such as Ivacaftor and the Ivacaftor/ 
Lumacaftor (Orkambi) combination therapy offer treatment for patients with specific mutations 
34-35
 but there are some mutation classes where CFTR modulators will not be effective, such as 
nonsense mutations, and so other therapeutic strategies are required. The low-volume 
hypothesis of CF lung disease links  increased activity of ENaC with ASL depletion in CF 
3
 and 
so reducing transepithelial sodium absorption through ENaC is an alternative target for 
therapeutics. 
11, 36
 The role of ENaC in regulating ASL volume has been validated in recent work 
showing that inhibition of ENaC proteolytic activation using the SPLUNC1 or peptide fragments 
37-39
 or QUB-TL1 
40
 successfully prevented dehydration of the ASL in CF HBEC monolayers. 
Small molecule inhibitors of ENaC suffer from rapid systemic absorption from the lung and are 
associated with side effects such as hyperkalaemia due to ENaC inhibition in the kidney or 
pulmonary oedema. 
11, 41-42
 We have therefore investigated ENaC silencing mediated by 
nanoparticles carrying siRNA.  
 We used siRNA to target the major subunit, αENaC. The αENaC subunit forms a 
sodium-conducting pore, while the other two subunits enhance its activity. 
43
 The α subunit is 
critical for sodium transport function and volume regulation as demonstrated in αENaC knockout 
mice, which die soon after birth due to a failure to clear their lungs of fluid. 
44
 In addition, it has 
been shown that a low mRNA abundance of αENaC in the nasal epithelium of premature infants 
is linked with respiratory failure. 
45
 Lastly, a mutation that leads to αENaC hyperactivity was 
found in patients with atypical CF. 
46
 
Nanoparticles offer protection to the siRNA during nebulisation and from nuclease attack 
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in lung fluids, and enable penetration of extracellular barriers such as mucus and the PCL 
47
 
before entering the epithelial cells by endocytosis. RTNs, comprising the oligolysine epithelial-
targeting peptide (Peptide E) and the liposome DOTMA/DOPE, self-assemble on mixing lipid 
and peptide components with siRNA to form cationic, monodisperse nanoparticles with a size of 
approximately 90 nm, which have been used previously for lung delivery of nucleic acids 
(including by nebulisation) in mice and pigs. 
25-26, 30-31, 48
 Similar RTN formulations can package 
and transfect siRNA efficiently 
20, 23-24, 49
 and so we are now investigating use of αENaC siRNA 
to assess its therapeutic potential in epithelial lung models in vitro and in vivo. 
We first assessed the ability of RTNs to penetrate mucus, which presents a physical 
barrier to nanoparticle siRNA delivery in the airways. Mucus is a gel-like layer, rich in charged 
mucin glycoproteins covering the lung epithelium and is particularly thick and sticky in the CF 
lung. 
50-51
 Differentiated ALI cultures of human airway epithelial cells produce copious amounts 
of mucus, which is particularly viscous from CF cells. 
52
 RTN diffusion in mucus from three 
sources was used including porcine gastric mucus, and human mucus from differentiated CF and 
non-CF airway epithelial cultures. RTN diffusion rates were lowest in CF mucus, consistent with 
its increased viscosity. RTNs diffused at similar rates to siRNA alone in CF and non-CF mucus 
despite their size and charge differences. The diffusion rates of RTNs were greater than those of 
cationic polystyrene nanoparticles of similar size used in cervicovaginal mucus, 
53-54
 suggesting 
that surface properties of RTNs contribute to their mucus mobility. 
32
 
 Silencing levels of αENaC by 30% from a single dose were achieved, which resulted in a 
significant reduction in amiloride-sensitive Isc compared with control siRNA and untransfected 
cells.  Silencing did not affect Rt indicating that there was no damage to the epithelial tight 
junctions by the nanoparticle complex directly or by decreased cell viability and that the changes 
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in Isc were a direct effect of reduced αENaC activity.   Interestingly βENaC, but not γENaC, was 
also silenced by αENaC siRNA. This was observed in other studies, 
17
 suggesting transcriptional 
feedback inhibition of βENaC by αENaC.  
Enhancement of silencing of αENAC to 50% by three sequential transfections in CFBE 
cells reduced the transepithelial potential to normal range values (-7 mV) in ALI cultures. 
55
 This 
may be a useful therapeutic biomarker as CF individuals display hyperpolarised nasal 
transepithelial potentials. 
56
 Silencing of αENAC also caused a significant reduction in fluid 
absorption and increased ASL depth to normal levels. Increased hydration of the epithelial 
surface was also indicated by the reduced total protein concentration in mucus washings from 
αENaC siRNA-treated cultures for at least a week post-transfection whereas the CFTR 
potentiator/corrector drug combination, VX-770 and VX-809, showed no effect on mucus 
protein concentration.  
We further hypothesised that increased ASL depth would reduce impedance of ciliary 
motility. Indeed we found that the ciliary beat frequency (CBF) in ENaC siRNA-treated CF cells 
was increased to ~15 Hz which compares well with normal CBF of approximately 16 Hz. 
57
 
Furthermore, the siRNA induced changes in CBF and fluid height after 3 doses, which was 
consistent with that reported for current drugs used to correct CFTR activity. VX-770 on its own 
increased CBF, 
58
 whereas the VX-770 and VX-809 combination increased ASL height 
59
 (both 
studies following 5 consecutive day treatments). 
This study suggests that silencing ENaC in the range of 30-50% is sufficient for 
restoration of epithelial ion transport balance, fluid transport and mucociliary properties. In 
previous αENaC silencing studies with siRNA, transfections were performed pre-ALI as 
transfections at ALI were ineffective, 
18
 although they reported correction of the short circuit 
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current and  increased ASL when using  siRNAs targeting both α and βENaC. 
18
 Another study 
showed that silencing of αENaC with a commercial transfection reagent in submerged cultures 
lasted for at least 3 days although they did not perform transfections at ALI. 
13
 They also 
reported 35-40% silencing in vivo with a liposomal formulation from a single administration 
which persisted at least 72 h. 
13
 Finally, an shRNA approach following lentiviral transduction of 
immortalized and primary cell lines used αENaC as their target. 
12
 The authors transduced 
primary cells before the formation of tight junctions, unlike our fully differentiated cell 
approach, and showed up to 60% silencing. Similar to our findings they have shown that 
reducing mRNA results in proportional changes in the short circuit current responses and also 
reduced net apical to basal fluid flux. In addition, they demonstrated that, at a high lentiviral 
dose, the βENaC mRNA was reduced but γENaC was not which is in agreement with our 
findings. 
We finally quantified ENaC silencing, after single or repeat siRNA dosing (by 
oropharyngeal instillation) in the lungs of normal mice. The tolerance of repeated dosing 
supports the hypothesis that our nanoparticles do not induce neutralising antibodies which is 
important for a potential life-long therapy. Minimal effective modulation of ENaC activity by 
repeated dosing of siRNA is likely to be much safer than complete inactivation of αENaC since 
this could result in negative effects such as oedema observed in lungs of ENaC knockout mice. 
44
 
There were no significant adverse effects of repeated dosing of RTNs in mice as judged by body 
weight and behaviour. There was only minimal focal inflammation assessed histologically and 
the nanocomplex biodistribution was restricted to the lungs. Transfection experiments at ALI 
with human CFBE cells suggested that silencing of αENaC in the range of 30-50% was sufficient 
for restoration of epithelial ion transport balance, fluid transport and mucociliary properties. We 
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have shown that RTNs achieve these levels of silencing in mice and that the silencing is 
persistent for at least one week.  These findings support the translational potential of this 
nanoparticle-mediated siRNA therapy for CF. 
In summary, we have described nanoparticles that can penetrate mucus effectively and 
deliver siRNA to the airway epithelium and that silencing of αENaC can be achieved in vitro and 
in vivo leading to improved hydration and mucociliary function in CFBE monolayers. Other 
studies have also shown functional correction of airway epithelial cells but only by transfection 
prior to ALI culture. RTNs represent a powerful new tool for siRNA transfection studies in 
differentiated respiratory epithelial cells and in vivo. The potential to regulate ENaC to a 
minimally effective level, the persistence of silencing for at least one week and restriction of 
distribution to the lung after airway administration indicates translational potential and suggests 
advantages in efficacy and safety over orally-administered, small molecule drugs.  
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Figure Legends 
Figure 1 Nanoparticles translocate vertically through the mucus barrier. Cy3-siRNA alone 
nanocomplexes containing Cy3-siRNA or fluorescent polystyrene nanoparticles (PS) were 
investigated for their translocation potential through (A) pig gastric mucus, (B) normal human 
airway mucus and (C) CF human airway mucus. The siRNA that is labelled with Cy3 is 
targeting GAPDH. The experiments were repeated on three occasions and each point is the mean 
± SEM of triplicate measurements.  
 
Figure 2 ENaC expression over time of primary cells growing at ALI and silencing of ENaC. 
(A) The fold-difference in endogenous αENaC gene expression relative to β-actin was quantified 
by qRT-PCR in CFBE cells from the start date of ALI cultures (mean of n=3 per time point). 
Points represent mean values ± SEM. (B) RTN formulations containing either αENaC siRNA or 
control siRNA at 100 nM were used in transfections of CFBE cells grown at ALI for 6 weeks. 
Transfections were performed once (single) or sequentially every other day (triple) and the 
percentage of silencing was calculated 48 h after the last transfection (n=3 per formulation). The 
middle horizontal lines represent the median values. Silencing is normalised to the mean control 
siRNA set at 100%. (C) CFBE cells grown at ALI were transfected with RTN formulations 
containing either αENaC siRNA or control siRNA at 100 nM and the percentage of silencing of 
α, β and γ ENaC subunits was then calculated 48 h after transfection (n=3 per formulation). The 
middle horizontal lines represent the median values. Silencing is normalised to the mean control 
siRNA set at 100%. Mann-Whitney U non-parametric tests were performed and no statistical 
significant differences were achieved. 
 
Page 26 of 63
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 26
 
Figure 3 Single transfection of CFBE air-liquid interface cell monolayers with nanocomplexes 
containing αENaC siRNA reduces the amiloride-sensitive short circuit current (Isc). (A) A 
schematic highlighting experiments performed after single or triple transfections on CFBE cells 
grown at ALI. (B) Representative Isc traces from CFBE monolayers in Ussing chambers of cells 
treated with 100 nM αENaC siRNA or control siRNA or untreated cells. (C) The change in Isc 
(∆Isc) after application of 10 µM amiloride is shown for the αENaC siRNA-treated cells (Ussing 
chambers; n=6), the control siRNA-treated cells (n=8) and the untreated CFBE cells (n=5). 
Median values are presented as bars and IQR by upper and lower horizontal lines, with statistical 
significance determined by the Mann-Whitney U non-parametric test. Asterisks indicate 
comparisons of specific formulations with statistical significance (*, p<0.05; **, p<0.01). (D) 
Transepithelial potential (Vt) of αENaC siRNA-treated monolayers of CFBE cells cultured for 4 
weeks on ALI. Wells were triple transfected with 100 nM αENaC siRNA (n=5) or control 
siRNA (n=5) and then Vt measurements performed 3 days after the last transfection using 
Scanning Ion Conductance Microscopy (SICM). Further samples were treated with 10 µM VX-
809 1 day prior to Vt measurement, and treated with 10 µM VX-770 during measurement (for 
approximately 20 minutes; n=4). Median values are presented as bars and IQR by upper and 
lower horizontal lines. Mann-Whitney U non-parametric tests were performed and no statistical 
significant differences were achieved. 
 
Figure 4 Effect of triple transfections of CFBE ALI cell with nanocomplexes containing αENaC 
siRNA. The CFBE cells were cultured in snapwells for 4 weeks then treated with 100 nM 
αENaC siRNA or control siRNA at 48 h intervals and the measurements performed 3 days after 
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the third dose. (A) ASL depth measurements of CFBE monolayers as determined by confocal 
microscopy.  XZ representative images of fluorescently-labelled ASL (red) and cells (green). 
Top:  untreated cells, middle: cells transfected 3 times with 100 nM of control siRNA and 
bottom: cells transfected 3 times with 100 nM of αENaC siRNA. A white bar has been included 
to denote the ASL measurement. (B) ASL depth measurement of each treatment group (n=4). 
Bars represent mean ± SEM, while asterisks indicate statistical significance of comparisons 
between the αENaC siRNA-treated cells versus the controls (***, p<0.001) determined by 
determined by an ANOVA test followed by Bonferroni's post-hoc test. (C) Effect of αENaC 
siRNA, control siRNA and VX-770 and VX-809 on ciliary beat frequency (CBF) of CFBE cells 
grown at ALI. For each experimental condition (n=10), readings of CBF were calculated from 
ten ciliated areas in the snapwell and the data represent the mean ± SEM. Asterisks indicate 
comparisons of specific formulations with statistical significance (*, p<0.05; **, p<0.01; ***, 
p<0.001) determined by an ANOVA test followed by Bonferroni's post-hoc test. (D) 
Transepithelial fluid transport through human CFBE cells. Net fluid absorption rate was 
measured 4 days after cell treatment with a control siRNA or with αENaC siRNA. Bars represent 
the median value with IQR shown by the horizontal lines (n=4), while asterisks indicate 
statistical significance (*, p<0.05) determined by Mann-Whitney U non-parametric tests. 
 
Figure 5 Protein concentration in mucus collected at different time points from transfected or 
untreated CFBE cells grown at ALI and in vitro silencing after 3 transfections. Mucus collections 
were done (A) 2 days after the first transfection (αENaC siRNA-tretated, n=6; control siRNA-
treated, n=3; untreated controls, n=3), (B) 2 days after the second transfection (αENaC siRNA-
tretated, n=6; control siRNA-treated, n=3; VX-770 and VX-809-treated, n=3; untreated controls, 
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n=3) and (C) 7 days after the third transfection (αENaC siRNA-tretated, n=6; control siRNA-
treated, n=3; VX-770 and VX-809-treated, n=3; untreated controls, n=3). The concentration 
levels were normalised to those of the untreated cells. (D) Formulations containing either 100 
nM αENaC siRNA (n=6) or control siRNA (n=3) were used in three sequential transfections of 
CFBE-BMI-1 cells grown at ALI for 4 weeks and the percentage of silencing was calculated 8 
days after the third transfection. Silencing was normalised to the mean control siRNA set at 
100%. The middle horizontal lines represent the median values. Asterisks indicate comparisons 
of specific formulations with statistical significance (*, p<0.05) determined by Mann-Whitney U 
non-parametric tests. 
 
Figure 6 In vivo lung administration of siRNA-containing nanocomplexes. (A) Uptake of 
Dy677-siRNA formulations following oropharyngeal administration. 24 h later the mice were 
culled (n=3 per group) and organs (heart, lung, liver, kidneys, spleen and intestines) were 
extracted and imaged for fluorescence. (B-D) The remaining αENaC mRNA was quantified by 
qRT-PCR in C57BL6 female mice after instillation of cationic nanocomplexes containing 16 µg 
αENaC siRNA (n=7) or control siRNA (n=6) at (B) 48 h and (C) 7 days. (D) The amount of 
remaining αENaC mRNA detected by qRT-PCR in C57BL6 female mice at 72 h after the last of 
3 instillations of cationic nanocomplexes containing 16 µg αENaC siRNA (n=8) or control 
siRNA (n=7).  Silencing was normalised to the mean control siRNA set at 100%. Medians and 
IQRs are presented by horizontal lines. Asterisks indicate comparisons of specific formulations 
with statistical significance (*, p<0.05; **, p<0.01; ***, p<0.001) determined by Mann-Whitney 
U non-parametric tests. 
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Figure 7 In vivo delivery of siRNA-containing nanocomplexes. Representative images of H&E 
stained murine lung sections following single (A) and triple (B) instillations of cationic αENaC 
siRNA nanocomplexes (n=3 for both), or a triple instillation (n=3) of cationic control siRNA 
nanocomplexes (C). All triple-instilled treated mice received 3 doses of nanocomplexes 
containing 16 µg siRNA on alternate days and the lungs were harvested 48 h after the third 
instillation. The mice that had one instillation of nanocomplexes containing 16 µg siRNA, also 
had their lungs harvested 48 h following instillation. Scale bars = 100 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 30 of 63
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 30
Particle Diffusion 
in PGM 
(cm2 s-1) 
Dm/Dw 
(PGM) 
Diffusion 
in NM  
(cm2 s-1) 
Dm/Dw 
(NM) 
Diffusion 
in CFM 
(cm2 s-1) 
Dm/Dw 
(CFM) 
siRNA 3.75 x 10-9 
 
1.57 x 10-2 
 
1.31 x 10-8 
 
1.11 x 10-2 
 
2.33 x 10-9 
 
2.66 x 10-3 
 
RTN 1.38 x 10-8 
 
1.93 x 10-1 
 
8.71 x 10-9 
 
9.12 x 10-2 
 
2.67 x 10-9 
 
3.74 x 10-2 
PS 5.75 x 10-9 4.82 x 10-2 - - N/A N/A 
 
Table 1. A comparison of the nanoparticle effective diffusion rate in mucus (Dm) and the 
effective diffusion rate in water (Dw) of the receptor-targeted nanocomplex (RTN), polystyrene 
nanoparticles (PS) and siRNA alone through 3 different types of static layers of mucus. Dm/Dw is 
the relative restriction of diffusion in mucus compared to water. N/A= data not applicable as 
effective translocation was not achieved. PGM= pig gastric mucus, NM= normal human airway 
mucus and CFM= cystic fibrosis human airway mucus. 
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Nanoparticles translocate vertically through the mucus barrier.  
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ENaC expression over time of primary cells growing at ALI and silencing of ENaC.  
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Single transfection of CFBE air-liquid interface cell monolayers with nanocomplexes containing αENaC siRNA 
reduces the amiloride-sensitive short circuit current (Isc).  
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Effect of triple transfections of CFBE ALI cell with nanocomplexes containing αENaC siRNA.  
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Protein concentration in mucus collected at different time points from transfected or untreated CFBE cells 
grown at ALI and in vitro silencing after 3 transfections.  
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In vivo lung administration of siRNA-containing nanocomplexes.  
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In vivo delivery of siRNA-containing nanocomplexes.  
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Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in 
human cystic fibrosis cells and in mouse lung 
 
Aristides D. Tagalakis, Mustafa M. Munye, Rositsa Ivanova, Hanpeng Chen,  Claire M. Smith, 
Ahmad M. Aldossary, Luca Z. Rosa, Dale Moulding, Josephine L. Barnes, Konstantinos N. 
Kafetzis, Stuart A. Jones, Deborah L. Baines, Guy W.J. Moss, Christopher O’Callaghan, Robin 
J. McAnulty, and Stephen L. Hart  
 
ONLINE DATA SUPPLEMENT 
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Supplemental Methods 
 
Materials 
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids, 
Inc. (Alabaster, AL, USA). The targeting peptide E (K16GACSERSMNFCG) was synthesised 
by China Peptides (Shanghai, China). Pig stomachs were purchased from Mutch Meats 
(Whitney, UK). The normal mucus from a healthy subject and the human mucus from a CF 
patient collected through the MucilAir
TM
 system were bought from Epithelix (Epithelix Sarl, 
Geneva, Switzerland). Amine modified polystyrene nanoparticles, sodium chloride, ethylene 
diamine tetra acetic acid (EDTA) and phenylmethyl sulfonyl fluoride (PMSF) were purchased 
from Sigma-Aldrich (Dorset, UK). The αENaC siRNA sequence (5’-
GCAGUGAUGUUCCUGUUGA-3’) was selected from an initial comparison of four candidate 
siRNAs in transfections of 16HBE14o- cells (as it gave the highest silencing) and were all 
obtained from Thermo Fisher Scientific (Northumberland, UK) for in vitro transfections.  The 
αENaC siRNA for in vivo administration (gene id: Scnn1a - AM16830) was obtained from Life 
Technologies (Paisley, UK). Non-targeting control siRNA was obtained from Thermo Fisher 
Scientific (Northumberland, UK) and from Life Technologies (Paisley, UK). Cy-3 Silencer 
GAPDH siRNA was bought from Thermo Fisher Scientific (Northumberland, UK) and used for 
the mucus translocation studies. VX-770 and VX-809 were bought form Generon (Maidenhead, 
UK). GlyH-101 (1) was bought from Merck Chemicals (Nottingham, UK) and Forskolin from 
Cambridge Bioscience (Cambridge, UK). All other chemicals were bought from Sigma-Aldrich 
(Dorset, UK). 
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Liposome and Nanocomplex Formation 
Lipids were dissolved in chloroform at 10 mg/mL then a lipid film was produced in a rotary 
evaporator by slowly evaporating the chloroform. Lipids were rehydrated with sterile, distilled 
water whilst constantly rotated overnight, and then sonicated in a water bath to reduce their size. 
Cationic liposomes made were: DOTMA:DOPE at 1:1 molar ratio.  
Cationic receptor-targeted nanocomplex (RTN) formulations (at a weight ratio of 1:4:1, 
liposome: peptide: DNA or siRNA) were made by first adding the peptide to the liposome, 
followed by addition of the siRNA (or DNA) with rapid mixing and incubation for 30 minutes at 
room temperature (RT) to allow for complex formation. Non-targeted RTNs were made in the 
same way. 
 
Particle Sizing and Zeta Potential Measurements 
Nanocomplex preparations were diluted with distilled water to a final volume of 1 mL at a 
concentration of 5 µg/mL with respect to DNA or siRNA. They were then analysed for size and 
charge (ζ potential) using a Malvern Nano ZS (Malvern, UK). The following specifications were 
used: automatic sampling time of 10 measurements/sample, refractive index of 1.330, dielectric 
constant 78.5, viscosity 0.8872 cP and temperature of 25ºC. Dispersion Technology Software 
(DTS) version 5.03, which was provided by the manufacturer, was used for data processing.  
 
Porcine Gastric Mucus Preparation 
The stomachs of freshly slaughtered pigs were opened along their greater curvature, inverted, 
any food content removed mechanically. The stomachs were rinsed with double-distilled water 
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and the mucus lining was gently removed by scraping using a plastic spatula and transferred to a 
container containing a protease inhibiting buffer composed of 200 mM sodium chloride, 0.02 % 
(w/v) sodium azide, 5 mM EDTA and 1 mM PMSF. The mucus was mixed well with an equal 
volume of the protease inhibiting buffer and homogenised with a mixer for 2 min. The mucus-
containing mixture was centrifuged at 11,200 g for 45 min at 4°C. The supernatant was poured 
into Visking dialysis tubing (MWCO: 12-14 kDa, Fisher Scientific, Loughborough, UK) and 
dialysed against deionised water for 24 h. The dialysed mucus solution was concentrated using 
an Amicon ultra-filtration stirred cell (Model 8400, 10 kDa membrane, Merck Millipore, UK) 
under nitrogen at a pressure of 40 psi and at 4°C. The retained mucus sample was collected into a 
bottle and frozen at -20°C until used. 
 
Static Mucus Diffusion 
Three different types of mucus were used: pig gastric mucus prepared in-house as above and 
non-CF and CF human mucus supplied commercially by Epithelix Sarl (Geneva, Switzerland). A 
35 µm thick mucus barrier was established by application of 1 µl of pig gastric mucus, human 
CF or non-CF mucus to Transwell membranes (Costar, UK) and equilibrated at 37°C for 0.5 h. 
The mucus barrier thickness and confluence was confirmed using microscopy and the flux of 
sodium fluorescein demonstrated it was a rate limiting barrier. The translocation of the siRNA 
alone, the RTN and commercial cationic polystyrene nanoparticles was determined over time 
from an apical donor nanosuspension into an aqueous receiver fluid. 600 µL of Tris buffer pH 
7.4 was used as the receiver fluid. 3 µL of nanoparticle suspensions containing Cy3-siRNA or 
siRNA alone at a concentration of 140 ng/µl were applied onto the surface of the barrier. At 
appropriate intervals, samples were removed from the receiver chamber and a ‘fit for purpose’ 
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(in terms of precision and limit of detection) fluorescence spectroscopy method was used for 
detection at a maximum excitation of 550 nm and emission of 570 nm (FLx800 Microplate 
Fluorescence Reader, Bio-TEK Instruments, Swindon, UK). The cumulative concentrations 
(ng/cm
2
) of translocated nanoparticles were quantified and plotted over time and the effective 
diffusion rates in mucus (Dm) using Fick’s law 
h
DC
dt
dM
=  
where 
dt
dM
was the flux, D was the diffusion coefficient, C was the concentration of the 
permeant in the donor solution and ℎ	was the thickness of the barrier) and the effective diffusion 
rates in water (Dw) using Stokes’ law 
r
KT
D
πη6
=       
(where D is the diffusion coefficient, K is the Botlzman constant, T is the temperature, η is the 
viscosity and r is the particle radius) were also calculated.  
  
Cell Culture and Transfections 
The 16HBE14o- cells (kindly provided by Dieter Gruenert, California Pacific Medical Center 
Research Institute, San Francisco, CA, USA) were maintained in Minimum Essential Medium 
Eagle’s modification (Sigma-Aldrich, Dorset, UK) at 37°C in a humidified atmosphere with 5% 
CO2. Tissue culture medium was supplemented with 10% heat-inactivated foetal bovine serum 
(FBS, Life Technologies, Paisley, UK), 2 mM L-glutamine (Life Technologies) and 0.1 mM 
non-essential amino acids (Sigma-Aldrich, Dorset, UK). Cystic Fibrosis Bronchial Epithelial 
cells (primary CFBE) and Normal Human Bronchial Epithelial cells (primary NHBE) were 
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obtained from Epithelix (Epithelix SàRL, Genève, Switzerland). Primary cells were transduced 
in house (2) with a lentiviral vector expressing the anti-senescent BMI-1 oncogene, obtaining 
CFBE-Bmi1 (CFBE) and NHBE-Bmi1 (NHBE) cells. Primary cells in submerged cultures were 
grown on 1% collagen-coated plastic flasks (PureCol® Bovine Collagen Solution, Type I, 
Advanced BioMatrix, San Diego, CA, USA) in Bronchial Epithelial Growth Medium (BEGM, 
Lonza) supplemented with Bovine Pituitary Extract, hydrocortisone, Human Epidermal Growth 
Factor, epinephrine, transferrin and insulin. Submerged cultures were transfected in 24 well 
plates (7x 10
4
 cells per well) and transfected with nanocomplexes prepared as described above 
and diluted with OptiMEM (Life Technology, Paisley, UK) at different siRNA concentrations in 
replicates of 3. Plates were centrifuged at 400g for 5 min and then incubated for 4 h at 37°C. The 
transfection solution was then removed and replaced with complete media. The plate was then 
incubated for 48 h to determine expression of the gene. 
For ALI culture, primary cells were grown in 12 mm collagen-coated transwell or 
snapwell inserts (Polyester (PET) Membrane Transwell-Clear Inserts, Corning, Corning Inc. Life 
Sciences, Tewksbury, MA, USA) at a seeding density of 1.5 × 10
5
 or 1 × 10
6 
viable cells per 
insert. Two days after seeding on transwells or snapwells, the BEGM media was removed from 
the apical side of the insert and the basolateral media changed to BEGM ALI medium (1:1 
DMEM-Hi glucose: BEGM containing supplements) supplemented with 100 nM retinoic acid 
(Sigma-Aldrich, Dorset, UK). Medium was changed 3 times per week and mucus produced on 
the apical surface was removed once per week by gentle washing with PBS. Cells were 
transfected in snapwells with siRNA nanocomplexes at 100 nM final concentration (diluted with 
OptiMEM) by applying 1000 µl to the basolateral surface and 125 µl to the apical surface (no 
mucus was removed prior to transfection)  and incubated for 4 hours at 37°C.  The transfection 
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solution was then removed and replaced with ALI media.  The plate was then incubated for 48 h 
or longer to determine gene expression or to perform functional studies. Transepithelial electrical 
resistance (Rt) of CFBE monolayers grown at ALI was measured at regular intervals using the 
EVOM Voltohmmeter (WPI, Hitchin, UK). 
For certain transfections, 48h after the transfection or at different time points the apical 
surface was washed with 75 µl of PBS to collect the mucus. The amount of protein present in 
each mucus sample was determined with the Bio-Rad protein assay reagent (Bio-Rad 
Laboratories, Hemel Hempstead, UK) in a FLUOstar Optima luminometer (BMG Labtech, 
Aylesbury, UK). 
 
Ussing Chamber Studies 
Confluent CFBE monolayers were grown on snapwell clear membrane supports (Corning, UK) 
at ALI for 3 weeks and treated with or without nanoparticles. 48 h after treatment, they were then 
mounted into Ussing chambers and bathed from both sides with physiological saline containing 
(in mM) NaCl 117, NaHCO3 25, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, CaCl2 2 and D-glucose 11 
(pH 7.4). This was maintained at 37°C and gassed with a premixed gas (21% O2 + 5% CO2). 
Monolayers were maintained under open-circuit conditions and the spontaneous transepithelial 
potential (Vt) was monitored until a stable value was reached (∼15 min) using a DVC 4000 
voltage/current clamp and recorded via a PowerLab computer interface. Drugs were added in the 
order of amiloride (10 µM, apical), forskolin (25 µM, apical and basolateral) and GlyH-101 (10 
µM, apical). NHBE cells were used as controls. 
 
ASL Depth Measurement  
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CFBE cells grown in snapwells in ALI were transfected 3 times (every other day) with 
nanocomplexes containing siRNA to ENaC (n=4) or control siRNA (n=4) or were left untreated 
as controls (n=4). ASL depth (i.e. depth of both the mucus and PCL layers) was measured 72 h 
after the last transfection using confocal microscopy. The ASL in each snapwell was washed 
twice with PBS and then labeled with 20 µl PBS containing 2 mg/ml Rhodamine B 
isothiocyanate-dextran (10 kDa; Sigma-Aldrich, Dorset, UK) by apical application the day prior 
to the experiment. The following day the CFBE cells were stained using 5 µM Calcein-AM 
(Thermo Fisher Scientific, Northumberland, UK) dissolved in culture medium for at least 60 min 
and introduced to the basolateral compartment of the insert. Perfluorocarbon (300 µl; Sigma-
Aldrich, Dorset, UK) was added to the apical compartment of the insert in order to prevent ASL 
evaporation. Fluorescent images of the epithelial layer and ASL height were obtained using a 
confocal microscope (Zeiss AxioObserver LSM 710 40x/NA1.2 plan-apochromat water 
objective, Jena, Germany). Samples were imaged in a #1.5 glass bottom dish (FD35, Fluorodish, 
World Precision Instruments, Hitchin, UK). Z stack acquisition used the optimal z-step as 
calculated in the Zen Software. For each snapwell, 5 different microscope fields randomly 
chosen were XZ scanned. Images were analysed with ImageJ/Fiji, using a macro to resliced 
images in an XZ orientation and threshold the ASL stain to produce a binary image for accurate 
manual height measurements. In each microscope field, the ASL height was measured in 9 
separate regions randomly determined over the surface of the monolayer and then averaged. 
 
Transepithelial Potential 
 
Cystic fibrosis bronchial epithelial cells (CFBE), cultured in snapwells at ALI, were left 
untransfected or transfected 3 times (every other day) with nanocomplexes containing siRNA to 
Page 46 of 63
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 9
ENaC or control siRNA and then placed in an environmental chamber. The transepithelial 
potential (Vt) of these samples was measured with the pipette immersed in the ASL using a 
Scanning Ion Conductance Microscope (SICM; OpenIOLabs, Cambridge, UK) paired with an 
Axopatch 200B amplifier (Molecular Devices, CA, USA). Vt measurements were conducted 
using the amplifier in current clamp mode (I=0 mV). Vt was defined as the electrical potential 
between a high-resistance borosilicate pipette (R>80 MΩ) immersed directly into the ASL, and 
an Ag/AgCl bead electrode immersed in Ringer’s solution on the basolateral side. In certain 
wells, the CFTR corrector VX-809 (10 µM) was added on the basolateral surface 1 day prior to 
ASL depth measurement, followed by addition of the potentiator VX-770 (10 µM) during 
measurement (again on the basolateral surface for approximately 20 min). 
 
Transepithelial Fluid Transport Measurement 
To quantify fluid absorption, CF cells were cultured in ALI as explained above. Following three 
sequential transfections (on alternate days) with ENaC or control siRNA, the apical surface of 
the cells was washed 48 h after the last transfection with 500 µl of a saline solution at RT 
containing (in mM): 137 NaCl, 2.7 KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 1 CaCl2, 0.5 MgCl2. After 
washing, the apical side of the epithelium was covered with 150 µl of the same solution and 200 
µl of mineral oil to prevent evaporation (3) and the cells returned to the incubator. After 24 h, the 
apical fluid was carefully removed, centrifuged to separate the mineral oil, and the volume of 
aqueous phase measured. The net flux across the epithelium is calculated as J= (Vi-Vf)/At, where 
Vi and Vf are the initial and final apical volumes, A is the = epithelium area, and t is the time 
interval between addition of Vi and recovering of remaining fluid Vf. 
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Assessment of Ciliary Beating 
Respiratory primary CFBE cell cultures grown in snapwells in ALI were transfected 3 times 
(every other day) with nanocomplexes containing siRNA (αENaC or control) or treated with 
VX-770 and VX-809 as above or left untreated.  The cultures were not washed for the duration 
of the experiment. 5 days after the last transfection they were placed in an incubation chamber 
(37°C, 5% CO2) and were observed via an inverted microscope system (Nikon, UK) equipped 
with an ORCA-Flash4.0 V2 Digital CMOS camera (Hamamatsu, Japan). For each experimental 
condition, readings of ciliary beat frequency (CBF) were calculated from ten ciliated areas in the 
snapwell using ciliaFA software as previously described (4, 5).   
 
Western Blot 
Transfections for protein extraction were performed in a 6-well plate. The protein extraction 
procedure was performed on ice. Media was aspirated and cells were washed 3 times with ice-
cold PBS. 30 µL of RIPA buffer supplemented with PMSF (Invitrogen, Paisley, UK) and 
protease inhibitor cocktail (Invitrogen, Paisley, UK) were added per well and incubated for 1 h 
on ice. Cells were then scraped and transferred in a 1.5 mL Eppendorf tube and kept on ice for 
30 min vortexing every 10 minutes. Cells were then centrifuged at 14,000xg for 10 min at 4°C 
and the supernatants collected (cell lysates). The amount of protein in the lysates was measured 
with the bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Northumberland, 
UK) reading the absorbance at 595nm in a FLUOstar Optima luminometer (BMG Labtech, 
Aylesbury, UK).  
Approximately 30 µg of the protein lysate were denatured at 95 °C for 5 min and loaded 
onto a 4-12% NuPAGE Bis-Tris pre-cast polyacrylamide gel. The gel was run at 100V for 15 
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min and 150V for 1 h in 1X NuPage running buffer. Proteins were transferred from the gel to a 
nitrocellulose membrane at 25V for 2.5 h in 1X NuPage transfer buffer (Life Technologies, 
Paisley, UK). The membrane was rinsed in di-ionised H2O), washed 3x for 5 min in Tris-
buffered saline/Tween (TBS-T) and subsequently incubated in a blocking buffer containing 5% 
milk powder in TBS-T for 1 h at RT. The membrane was then incubated with primary antibody 
in blocking buffer at 4 °C overnight. The primary antibodies used were polyclonal rabbit anti-α 
ENaC (PAI-920; Thermo Fisher Scientific, Northumberland, UK) at 1:750 dilution and mouse 
monoclonal anti-β-actin (AC-15; Sigma-Aldrich, Dorset, UK) at 1:5000 dilution. The 
membranes were then washed 3x for 5 min in TBS-T and incubated in secondary antibody in 
blocking buffer at RT for 1h. The secondary antibody for αENaC was polyclonal swine anti-
rabbit HRP (horseradish peroxidase) at 1:1700 dilution (Dako, Ely, UK) and for β-actin 
polyclonal goat anti-mouse HRP at 1:1000 dilution (Dako, Ely, UK). Then the membranes were 
washed 3x for 5 min in TBS-T and developed with Clarity Western ECL substrate (1:1 of 
peroxidase and luminol/enhancer reagent; Bio-Rad, Hemel Hempstead, UK). The western blot 
densities were analysed using ImageJ software (NIH, Bethesda, USA).  
 
In Vivo Delivery and Histology of Lung Tissues 
Female C57Bl6 mice 6-8 week old were purchased from Charles River (Margate, UK). All 
procedures were approved by UCL animal care policies and were carried out under Home Office 
Licenses issued in accordance with the United Kingdom Animals (Scientific Procedures) Act 
1986 (UK). Cationic nanocomplexes were prepared as described above at a final siRNA 
concentration of 0.29 mg/mL. Mice were instilled oropharyngeally following gaseous isoflurane 
induced anaesthesia (6, 7) with nanocomplexes in 55 µL (made in 5% glucose, v/v) containing 
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16 µg siRNA (αENaC or control siRNA), with untreated mice used as controls. In biodistribution 
studies, mice were instilled oropharyngeally as above with nanocomplexes in 55 µL (made in 5% 
glucose, v/v) containing 16 µg of siRNA-Dy677. Experiments were performed with replicates of 
3 mice. 24 hours after injection, the mice were culled and organs (lung, liver, heart, kidneys, 
intestines and spleen) were resected and imaged using an IVIS Lumina Series III imaging system 
(PerkinElmer, Seer Green, UK).  The images were processed using the Living Image software 
(PerkinElnmer, Seer Green, UK). 
48 h or 7 days post-administration and the lungs excised and snap-frozen in liquid 
nitrogen and stored at -80°C till needed. In other studies siRNA-containing nanocomplexes were 
instilled 3 times (every other day) and the lungs excised 72 h after the 3
rd
 instillation. 
For the histology studies, mice were culled 48 h following oropharyngeal instillation of 
nanocomplexes and the lungs inflation fixed in situ with 4% paraformaldehyde at a pressure of 
20 cm. The lungs were placed in 4% (w/v) PFA for 3 h followed by overnight incubation in 15% 
(w/v) sucrose/PBS and then a brief wash in 50% (v/v) ethanol and stored in 70% (v/v) prior to 
processing to paraffin wax.  
 
RNA Extraction From Cells and Mouse Tissues 
After 48 h, submerged cells were trypsinised and homogenised with Qiagen shredders (Qiagen, 
Crawley, UK). Cells grown on ALI were washed in PBS, scraped, centrifuged at 14,000g for 5 
min and homogenised with Qiagen shredders. Total RNA was extracted from the homogenate 
using the RNeasy Kit (Qiagen, Crawley, UK), following the manufacturer’s protocol and each 
sample underwent DNase treatment (Invitrogen, Paisley, UK) to eliminate any potential genomic 
DNA contamination. The samples were stored at -80 °C.  
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Mouse lungs were homogenised with the Precellys24 tissue homogenizer (2 cycles x 
5600 rpm, 30 sec per cycle). Total RNA was extracted from mouse lysates using the RNeasy kit 
according to the manufacturer’s instructions (Qiagen, Crawley, UK). RNA was checked for 
integrity using the Agilent 2100 Bioanalyzer (Wokingham, UK). All RNA samples had a RNA 
integrity number (RIN) of more than 9 indicating high quality RNA. Each sample underwent 
DNase treatment as above.  
 
Quantitative Real-time PCR (qRT-PCR) 
Total RNA (200 ng per reaction) was used in a one-step qRT-PCR (SensiFast Probe Hi-Rox 
One-Step Kit; Bioline, London, UK) that combines the reverse transcription with the quantitative 
PCR reaction. Human (Hs00168906_m1) or mouse (Mm01182998_g1) αENaC, human 
(Hs99999903_m1) or mouse β-actin (Mm00607939_s1), human βENaC (Hs01548617_m1) and 
human γENaC (Hs00168918_m1) were quantified by Taqman primers and probes (Thermo 
Fisher Scientific, Northumberland, UK). The qRT-PCR assays were performed in a Bio-Rad 
CFX96 Real-Time PCR Detection System with the following parameters: 45°C for 20 min, 95°C 
for 2 min and then 40 cycles at 95°C for 15 sec and 60°C for 1 min. Relative expression levels 
were calculated using the delta-delta Ct (2
−∆∆Ct
) method (8).  
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Supplemental Figure Legends 
Figure S1. Silencing efficiency of 16HBE14o- cells transfected with cationic ENaC siRNA 
nanocomplexes. (A) Representative western blot of αENaC protein from 16HBE14o- cells 
transfected with 75 nM of siRNA-containing nanocomplexes (n=3). αENaC major forms of 90 
kDa and 65 kDa bands are shown in the blot. Untr= untreated cells. (B) The quantification by 
densitometry analysis of the % of remaining αENaC protein of the above blot is shown for the 65 
kDa protein band of each group.    
 
Figure S2. Expression of the different ENaC subunits in primary CFBE cells grown at ALI. 
CFBE cells were grown at ALI for 4 weeks and were then harvested and qRTPCR was 
performed in order to determine the expression of the different ENaC subunits. αENaC and 
βENaC are expressed relative to γENaC which is set at 1 (n=3). The middle horizontal lines 
represent the median values while the upper and lower horizontal bars represent the IQR. 
Asterisks indicate comparisons of specific formulations with statistical significance (***, 
p<0.001; Mann-Whitney non-parametric tests were performed).  
 
Figure S3. Representative Isc traces from untreated NHBE monolayers in Ussing chambers. This 
figure was used in work we conducted simultaneously and has been very recently published. (2) 
 
Figure S4. Transepithelial electrical resistance (Rt) measurements on transfected and non-
transfected CFBE-Bmi1 monolayers. The monolayers were cultured in snapwells and transfected 
with 100 nM of αENaC siRNA or control siRNA or were left untreated. 48 h later their Rt was 
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measured. The middle horizontal lines represent the median values while the upper and lower 
horizontal bars represent the IQR (n=3-7). There was no statistical difference between the groups 
tested (Mann-Whitney non-parametric tests were performed). 
 
Figure S5. Radiant efficiencies (photons s
−1
 cm
−2
 steradian
−1
 per µW cm
−2
) of organs/tissues 
following oropharyngeal administration of nanocomplexes carrying Dy677-siRNA. 24 h later the 
mice were culled (n=3 per group) and organs (heart, lung, liver, kidneys, spleen and intestines) 
were extracted and imaged for fluorescence with the IVIS III system. The uptake of siRNA-
Dy677 was significantly more in the lungs when compared to the intestines, the latter being the 
only other organ where fluorescence was detected. *, p<0.05 (Mann-Whitney non-parametric 
tests were performed to compare uptake differences between organs). Radiant efficiencies were 
measured using a Living Image 4.0 software package. 
 
Figure S6. Weights of mice (in grams) (A) before and 7 days after a single instillation of 
nanocomplexes containing 16 µg siRNA and (B) during 3 instillations. Mann-Whitney non-
parametric tests were performed. Each individual mouse is represented by a symbol. The lines 
are the means of the weights for each group of mice. 
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Formulation Normal human 
mucus (ng/cm
2
) 
Cystic Fibrosis 
mucus (ng/cm
2
) 
Pig Gastric mucus 
(ng/cm
2
) 
RTN 961.5 ± 44.8 441.1 ± 52.7 1046.1 ± 47.6 
siRNA 917.3 ± 60.1 390.1 ± 15.8 472.0 ± 8.8 
Polystyrene beads not done 100.0 ± 57.6 782.7 ± 123.0 
 
 
Table S1.  Nanoparticle translocation through mucus. Cumulative concentrations through 
different mucus sources of the receptor-targeted nanocomplexes (RTN), siRNA and 
polystyrene nanoparticles (PS) were determined from the accumulated fluorescence over a 
period of 1 hour. Values are averages ± SEM. 
 
 
αENaC siRNA dose αENaC silencing % βENaC silencing % γENaC silencing % 
Single 30  51  0 
Triple 54  not done not done 
 
 
Table S2.  In vitro siRNA silencing of ENaC in epithelial cells. CFBE cells grown at ALI 
were transfected with RTN formulations containing either αENaC siRNA or control siRNA at 
100 nM. The percentage of silencing of α, β and γ ENaC subunits was calculated 48 h after 
transfection (n=3 per formulation). Values shown are the differences of the median silencing 
of ENaC siRNA treated group compared to their respective control siRNA group. 
 
 
αENaC siRNA dose αENaC Control siRNA Untreated 
Amiloride-sensitive (Isc) µA/cm
2
 6.4 (IQR:  
5.4-9.8) 
11.5 (IQR:  
10.1-14.1) 
14.3 (IQR: 
13.2-17.9) 
Rt   Ω cm
2
 693.5 (IQR: 
565.7-805.8) 
783.2 (IQR: 
711.1-953.2) 
676.7 (IQR: 
653.1-744.2) 
 
 
Table S3. The effects of siRNA transfection on amiloride-sensitive short circuit current 
Isc and transepithelial electrical resistance (Rt). Values are medians with the Interquartile 
range (IQR). 
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Analysis αENaC 
siRNA 
Control 
siRNA 
VX-770/  
VX-809 
CFBE 
NHBE 
untreated 
CFBE 
untreated 
Transepithelial 
potential (Vt),  mV 
-7.2 (IQR: 
-5.7 to -
12.2) 
-16.0 
(IQR: -
14.8 to -
19.0) 
-6.8 (IQR: -
6.7 to -12.7) 
-7.7 (IQR: -
6.3 to -11.6) 
not done 
ASL depth, µm 12.1 (IQR: 
10.7-14.9) 
7.9 (IQR: 
6.4-9.8) 
 
not done not done 8.2 (IQR: 
5.8-11.1) 
Ciliary beat 
frequency, Hz 
14.5 ± 0.5 11.9 ± 1.0 12.8 ± 0.5 not done 9.6 ± 0.7 
Net fluid 
absorption, 
µl/cm
2
/h 
0.9 (IQR: 
0.6-1.3) 
1.6 (IQR: 
1.3-1.9) 
not done not done 1.5  (IQR: 
1.1-1.9) 
 
 
Table S4. Effects of triple-dose αENaC silencing on transepithelial potential (Vt), airway 
surface liquid depth (ASL), ciliary beat frequency and net fluid absorption. Values are 
shown as mean ± SEM for ciliary beat frequencies. All other values are medians with the 
Interquartile range (IQR). 
 
 
 
siRNA dose % αENaC silencing 
48h-72h 
% αENaC silencing, 1 
week after administration 
Single 30 23 
Triple 58 not done 
 
 
Table S5.  In vivo silencing of αENaC.  Following αENaC siRNA administration, silencing 
was determined by qRT-PCR at 48 h and 1 week. Triple dosing was also performed and the 
percentage of silencing was calculated 72 after the final dose. Values shown are the 
differences of the median silencing of αENaC siRNA treated group compared to their 
respective control siRNA group. 
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 ITEM RECOMMENDATION Section/ Paragraph 
Title 1 Provide as accurate and concise a description of the content of the article 
as possible. 
      
Abstract 2 Provide an accurate summary of the background, research objectives, 
including details of the species or strain of animal used, key methods, 
principal findings and conclusions of the study. 
      
INTRODUCTION  
Background 3 a. Include sufficient scientific background (including relevant references to 
previous work) to understand the motivation and context for the study, 
and explain the experimental approach and rationale. 
b. Explain how and why the animal species and model being used can 
address the scientific objectives and, where appropriate, the study’s 
relevance to human biology. 
      
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or 
specific hypotheses being tested. 
      
METHODS  
Ethical statement 5 Indicate the nature of the ethical review permissions, relevant licences (e.g. 
Animal [Scientific Procedures] Act 1986), and national or institutional 
guidelines for the care and use of animals, that cover the research. 
      
Study design 6 For each experiment, give brief details of the study design including: 
a. The number of experimental and control groups. 
b. Any steps taken to minimise the effects of subjective bias when 
allocating animals to treatment (e.g. randomisation procedure) and when 
assessing results (e.g. if done, describe who was blinded and when). 
c. The experimental unit (e.g. a single animal, group or cage of animals). 
A time-line diagram or flow chart can be useful to illustrate how complex 
study designs were carried out. 
      
Experimental 
procedures 
7 For each experiment and each experimental group, including controls, 
provide precise details of all procedures carried out. For example: 
a. How (e.g. drug formulation and dose, site and route of administration, 
anaesthesia and analgesia used [including monitoring], surgical 
procedure, method of euthanasia). Provide details of any specialist 
equipment used, including supplier(s). 
b. When (e.g. time of day). 
c. Where (e.g. home cage, laboratory, water maze). 
d. Why (e.g. rationale for choice of specific anaesthetic, route of 
administration, drug dose used). 
      
Experimental 
animals 
8 a. Provide details of the animals used, including species, strain, sex, 
developmental stage (e.g. mean or median age plus age range) and 
weight (e.g. mean or median weight plus weight range). 
b. Provide further relevant information such as the source of animals, 
international strain nomenclature, genetic modification status (e.g. 
knock-out or transgenic), genotype, health/immune status, drug or test 
naïve, previous procedures, etc. 
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Housing and 
husbandry 
9 Provide details of: 
a. Housing (type of facility e.g. specific pathogen free [SPF]; type of cage or 
housing; bedding material; number of cage companions; tank shape and 
material etc. for fish). 
b. Husbandry conditions (e.g. breeding programme, light/dark cycle, 
temperature, quality of water etc for fish, type of food, access to food 
and water, environmental enrichment). 
c. Welfare-related assessments and interventions that were carried out 
prior to, during, or after the experiment. 
      
Sample size 10 a. Specify the total number of animals used in each experiment, and the 
number of animals in each experimental group.  
b. Explain how the number of animals was arrived at. Provide details of any 
sample size calculation used. 
c. Indicate the number of independent replications of each experiment, if 
relevant. 
      
Allocating 
animals to 
experimental 
groups 
11 a. Give full details of how animals were allocated to experimental groups, 
including randomisation or matching if done. 
b. Describe the order in which the animals in the different experimental 
groups were treated and assessed. 
      
Experimental 
outcomes 
12 Clearly define the primary and secondary experimental outcomes assessed 
(e.g. cell death, molecular markers, behavioural changes). 
      
Statistical 
methods 
13 a. Provide details of the statistical methods used for each analysis. 
b. Specify the unit of analysis for each dataset (e.g. single animal, group of 
animals, single neuron). 
c. Describe any methods used to assess whether the data met the 
assumptions of the statistical approach. 
      
RESULTS  
Baseline data 14 For each experimental group, report relevant characteristics and health 
status of animals (e.g. weight, microbiological status, and drug or test naïve) 
prior to treatment or testing. (This information can often be tabulated). 
      
Numbers 
analysed 
15 a. Report the number of animals in each group included in each analysis. 
Report absolute numbers (e.g. 10/20, not 50%2). 
b. If any animals or data were not included in the analysis, explain why. 
      
Outcomes and 
estimation 
16 Report the results for each analysis carried out, with a measure of precision 
(e.g. standard error or confidence interval). 
      
Adverse events 17 a. Give details of all important adverse events in each experimental group. 
b. Describe any modifications to the experimental protocols made to 
reduce adverse events. 
      
DISCUSSION  
Interpretation/ 
scientific 
implications 
18 a. Interpret the results, taking into account the study objectives and 
hypotheses, current theory and other relevant studies in the literature. 
b. Comment on the study limitations including any potential sources of bias, 
any limitations of the animal model, and the imprecision associated with 
the results2. 
c. Describe any implications of your experimental methods or findings for 
the replacement, refinement or reduction (the 3Rs) of the use of animals 
in research. 
      
Generalisability/ 
translation 
19 Comment on whether, and how, the findings of this study are likely to 
translate to other species or systems, including any relevance to human 
biology. 
      
Funding 20 List all funding sources (including grant number) and the role of the 
funder(s) in the study. 
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